MedTrace Logo

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

NCT00672191 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2013-01-29

No results posted yet for this study

Summary

The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping anti-HIV drugs, immunotherapy can control the HIV-1 virus.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

AGS-004

HIV-1 Immune Therapy

Sponsors & Collaborators

  • Argos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jean-Pierre Routy, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

  • Mona Loutfy, MD · Maple Leaf Clinic

  • Cecile Tremblay, MD · CHUM- Hotel Dieu de Montreal

  • John Gill, MD · Southern Alberta Clinic

  • Jean-Guy Baril, MD · Clinque Medical du Quartier Latin

  • Sylvie Vezina, MD · Clinque medicale l'Actuel

  • Jonathan B Angel, MD · The Ottawa Hospital

  • Sharon Walmsley, MD · UHN

  • Fiona Smaill, MD · Hamilton Health Sciences Corporation

  • Anita Rachlis, MD · Sunnybrook Health Sciences Center

  • Julio Montaner, MD · Providence Health Care Society

  • Jeffrey Jacobson, MD · Partnership Comprehensive Care Practice

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-08-31
Completion
2011-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00672191 on ClinicalTrials.gov